

# EVALUATION OF FERTILITY HORMONES IN TYPE 2 DIABETIC MALE SUBJECTS IN NAUTH, NNEWI.

## ABSTRACT

**Background and Aim of study:** To Assess the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone among type 2 diabetic male subjects in NAUTH, NNEWI.

**Methodology:** This was a cross sectional study carried out at Endocrinology unit, NAUTH Nnewi. A total of 134 participants were recruited for this study which comprised of 67 male type 2 diabetics mellitus subjects and 67 apparently healthy controls . The levels of testosterone, LH, FSH and glycated haemoglobin were analysed using ELISA and colorimetric assay methods respectively.

**Results:** Results from this findings showed that the mean levels of glycated hemoglobin (HbA1c), LH and FSH were significantly higher in test subjects compared with that of the control subjects ( $p < 0.05$ ). Conversely, the mean level of testosterone was significantly lower in the type 2 diabetic male subjects compared to that of the control subjects ( $p < 0.05$ ) In male type 2 diabetic participants, there was a significant positive correlation between the mean levels of HbA1c and the mean levels of LH ( $r = 0.385$ ,  $p = 0.001$ ) and FSH ( $r = 0.535$ ,  $p < 0.001$ ). Nevertheless, among the male type 2 diabetic participants, there was no significant correlation ( $p > 0.05$ ) between the mean HbA1c levels and testosterone. In the control group, there was a significant positive correlation ( $r = 0.461$ ,  $p < 0.001$ ) between the mean values of HbA1c and FSH.

**Conclusion:** This suggests there is hypogonadism which is indicative of an alteration in the hypothalamic-pituitary -gonadal axis and this could lead to infertility in type 2 diabetic male subjects.

**Key words:** Diabetes mellitus, glycated heamoglobin/HbA1c, FSH, LH, Testosterone.

## INTRODUCTION

Diabetes mellitus (DM) is one of the metabolic disorders which is characterized by hyperglycemia resulting from lack of insulin synthesis and secretion or reduced sensitivity of tissues to insulin<sup>1</sup>. According to WHO (2016), the 7th leading cause of death is diabetes and as of 2021 its been estimated that about 537 million people had diabetes mellitus with about type 2 diabetes prevailing more<sup>2</sup>. Furthermore, its been estimated that by 2045, approximately 783 million adults, or 1 in 8 people, will be living with diabetes, representing a 46% increase from the current figures<sup>2</sup>. Reports have shown percentage prevalence of diabetes mellitus in Nigeria to be within 0.8-4.4% with its rural and urban areas between 4.6-7%<sup>3,4</sup>. The pooled prevalence of Diabetes mellitus in the six geopolitical zones of Nigeria were 3.0% in the north-west, 5.9% in the North east, 3.8% in the North central zone, 5.5% in the south west, 4.6% in the south-east and 9.8% in the south south zone<sup>5</sup>.

According to Berta, Reproductive hormones are secreted from the anterior pituitary gland and they are: The follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH) and thyroid-stimulating hormone (TSH)<sup>10</sup>. LH, FSH and testosterone are major hormones of reproduction which directly control many aspects of gonadal development<sup>10</sup>. Male fertility can be assessed by measuring the serum levels of male fertility hormones such as: luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone<sup>12</sup>. FSH receptors are located on the membrane of Sertoli cells, while those of LH are on the Leydig cells. They coordinate to synthesize testosterone, maintain normal spermatogenesis, sperm health and density<sup>11</sup>. The gonadotropin releasing hormone (GnRH) secreted by the hypothalamus regulates the release and secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from anterior pituitary that in turn regulate testicular functions<sup>12</sup>. LH controls the production of testosterone by the Leydig cells which is located on the interstitium of the testis<sup>28</sup>. Testosterone is essential for male virilization as it combines with FSH to trigger and maintain spermatogenesis<sup>28</sup>. There will be a joint action of testosterone and FSH on the Sertoli cells this will limit the wall of seminiferous tubules that support germ cells undergoing development to become mature sperm. For the process of spermatogenesis to be initiated and continuously, Leydig cells must secrete more LH during puberty in order to maintain an increased amount of interstitial testosterone, which is necessary for male virilization and the maintenance of spermatogenesis in the male external genitalia<sup>28</sup>. In males, intratesticular hormone is actually 100 times more circular than peripheral blood<sup>28</sup>. Testosterone also stimulates erythropoietin which is responsible for higher levels of hemoglobin in males than in females. Testosterone tends to drop as age increases and because of this there is reduction in testicular size, drop in libido, lower bone density, decline in muscle mass, increased fat production and decreases in erythropoietin and thereafter leading to anemia<sup>40</sup>. These gonadal steroids as well as the pituitary gonadotropins, via feedback regulatory mechanisms, further establish physiological homeostasis and maintains normal reproductive functions<sup>11</sup>.

Prior reports have revealed an association between low serum testosterone levels and diabetes mellitus<sup>13,14</sup>. Also reports by Al hayek et al reported low serum levels of testosterone and elevated levels of LH in male diabetic subjects<sup>15</sup>. Hypogonadism has been characterized by Low testosterone levels followed by other features seen in hypogonadism which are : erectile dysfunction, poor morning erection, low libido etc<sup>17-19</sup>. About 6.0 -26% of male subjects with diabetes mellitus has been noted to have low testosterone levels<sup>16</sup>. Studies by Al fartosy showed an increased HbA1C levels being associated with LH,FSH and low testosterone levels<sup>25</sup>. This could be due to an imbalance between reactive oxygen species and antioxidant capacity which could result in oxidative stress<sup>26</sup>

Glycosylated haemoglobin/glycated haemoglobin (HbA1c) can be directly correlated to glucose levels and complications, and is recommended by international guidelines as the preferred measure when evaluating the overall control of diabetes and the patient's risk for complications<sup>21</sup>. Glycated haemoglobin is the most preferred assay for blood glucose determination because it provides a long term measure of the patient's blood glucose levels. It also provides the physician with a reliable means of monitoring patient's hyperglycemia without the need to request for fasting prior to testing like in fasting plasma glucose<sup>27</sup>. Hence, close monitoring of HbA1c levels is recommended for all diabetic patients and those with the potential for developing diabetes. It is also suggested that diabetic and non-diabetic patients with raised HbA1c levels should be clinically checked and monitored as a preventive intervention to avoid developing T2DM<sup>22</sup>. There is evidence according to Shewarni et al which revealed elevated levels of HbA1c in diabetic male patients<sup>27</sup>. The most significant modifiable risk factor for diabetes mellitus is obesity, and the diagnosis and definition of obesity are based on anthropometric measures<sup>23</sup>.

Waist circumference, waist to hip ratio, waist-to-height ratio, weight, height, and BMI<sup>23</sup> are measurements obtained from anthropometry; however, due to the historical use of BMI<sup>23</sup>, BMI is still primarily utilised among these anthropometric measurements in the classification of obesity<sup>24</sup>. Shi et al reported high levels of BMI in male diabetic patients with erectile dysfunction<sup>29</sup>. Elevations in anthropometric measurements have also been linked to hyperglycemia. Studies by Cheung et al. has revealed that one of the features of diabetes mellitus in men which causes low levels of testosterone is obesity<sup>20</sup>. The mechanism behind this is that, in obese men during peripheral conversion of testosterone to oestrogen there will be an attenuation in amplitude of leutinizing hormone pulses this could subsequently inhibit testosterone production, causing low testosterone levels<sup>20</sup>.

Long term complications of type 2 diabetes develop gradually, with infertility being one of them<sup>6</sup>. Infertility is a disease characterised by failure to establish a clinical pregnancy after 12 months of regular and unregular unprotected sex<sup>7</sup>. Males account for roughly 20–30% of infertility cases, while females account for another 20–30%, or about 50% of cases overall.<sup>7</sup> Studies have shown there are higher risk of

infertility from men who are diabetic when compared with control subjects<sup>8</sup> and evidence from studies by Ding et al. revealed the impact of diabetes mellitus on reproductive system with the following conditions being generated : dysfunction of hypothalamic pituitary gonadal axis, decreased testosterone and synthesis secretion, testicular failure, spermatogenesis disorder, erectile dysfunction, ejaculatory disorder etc .It is therefore imperative to evaluate the LH,FSH and testosterone and glyated heamoglobin levels in type 2 diabetic male subjects.

## **MATERIALS AND METHOD**

### **Study design**

This was cross-sectional study designed to assess some fertility hormones among type 2 diabetic male subjects in NAUTH Nnewi, Nigeria. A total number of One hundred and thirty-four (134) Participants were recruited randomly for this study. This comprised of Sixty-seven (67) type 2 diabetic male subjects and who were aged 40-65 years selected from endocrinology unit NAUTH, Nnewi and Sixty-seven (67) apparently healthy controls who were aged 40-65 years selected from staff of Nnamdi azikiwe university teaching hospital (NAUTH) Nnewi, Anambra state. Information on socio-demographic, medical history and lifestyle was obtained using a questionnaire. Body mass index (BMI) was derived using the height and weight measurement of subjects.

### **Ethical Clearance**

The ethical approval for this research was obtained from the ethics committee of Nnamdi Azikiwe University Teaching Hospital, Nnewi (NAUTH) with reference no: NAUTH/CS/66/vol.15/VER.3/338/2021/112.

### **Informed Consent**

Consent was sought and obtained from subjects prior to study. A written consent form was used.

### **Exclusion Criteria**

These were Individuals outside the age range of 40-65 years and Subjects with history of chronic diseases such as: chronic obstructive pulmonary disease, hypertension and thyroid disorders, Smokers and chronic alcohol drinkers and Known infertile subjects.

## **Specimen Collection**

Five millimeters (5mls) of whole blood was collected from the subjects using the venipuncture technique, 3mls of the blood sample was dispensed into plain sample container and 2mls dispensed in EDTA container. The sample dispensed into the plain sample container was allowed to stand for 10mins to clot and centrifugation performed at 4000rpm for 5minutes. The serum was separated and stored at -20°C until analysis of testosterone, LH, FSH. Sample in the EDTA container was used for the assay of Glycated Haemoglobin to ascertain glyceimic control.

## **Laboratory procedures**

### **Determination of Glycated Haemoglobin (HbA1c)**

Glycated Hamoglobin was determined by Immunoturbidimetric assay method as described by Metus *et al.*<sup>30</sup>.

### **Determination of Luteinizing Hormone Levels**

LH was determined using sandwich enzyme linked immunosorbent assay (ELISA) as described by Benard and Ongaro<sup>31</sup>.

### **Determination of Follicle Stimulating Hormone Levels**

FSH was determined using competitive enzyme linked immunosorbent assay (ELISA) was used as described by Ongaro *et al.*<sup>32</sup>.

### **Determination of Testosterone Hormone**

Testoteron was determined using Competitive enzyme immunoassay method (ELISA) as described by Tietz<sup>33</sup>.

## **Anthropometric measurement**

The weight and height of each participant were measured using a standard beam balance scale and a stadiometer respectively. Body mass index (BMI) was calculated as weight (kg) divided by height squared in meters.

$$\text{BMI}(\text{Kg}/\text{m}^2) = \text{Weight}(\text{Kg})/\text{Height}^2 (\text{m}^2).$$

## Statistical Analysis

Statistical package for social sciences version 23.0 was used for data analysis. The data obtained were analyzed using ANOVA, Independent t-test and Pearson Correlation. Results were deemed significant at  $p < 0.05$ .

## RESULTS

The result of analysis of variance showed the mean ( $\pm$  SD) value of BMI and age in male type 2 diabetic subjects and control group. The mean body mass index (BMI) of type 2 male diabetic subjects was observed to be significantly higher compared with that of the control subjects ( $30.57 \pm 4.83$  VS  $25.71 \pm 2.67$ ;  $P = 0.001$ ). Whereas, the mean value of age did not show any significant difference in type 2 diabetic male subjects compared to control group ( $P = 0.171$ ) See table 1.

The mean serum level of HbA1c was observed to be significantly higher in type 2 male diabetic subjects compared with that of the control subjects ( $8.56 \pm 1.22$  Vs  $5.25 \pm 0.31$ ;  $P = 0.001$ ). Also, the mean serum levels of LH and FSH was noted to be significantly higher in type 2 diabetic male subjects when compared with control group ( $10.74 \pm 4.50$  Vs  $4.88 \pm 1.36$ ;  $P = 0.001$ ) and ( $15.13 \pm 7.26$  Vs  $6.89 \pm 2.92$ ;  $P = 0.001$ ) respectively. However, the mean serum levels of testosterone was observed to be significantly lower in type 2 diabetic male subjects in comparison to the control group ( $2.89 \pm 1.05$  Vs  $2.89 \pm 1.05$ ;  $P = 0.001$ ). See Table 2

There was a significant positive correlation between the mean levels of HbA1c with mean serum levels of LH ( $r = 0.385$ ,  $p = 0.001$ ) and FSH ( $r = 0.535$ ;  $p = 0.001$ ) in type 2 diabetic male subjects. However, there was no significant correlation was noted in mean serum levels of HbA1c with mean serum levels of testosterone in the type 2 diabetic male subjects and control group ( $p > 0.05$ ). See table 3.

**TABLE 1:** Age and BMI in type 2 diabetic male subjects and control group (Mean± SD)

VARIABLE	TEST GROUP (n=67)	CONTROL GROUP (n=67)	P-VALUE	SIGNIFICANCE
BMI (KG/M <sup>2</sup> )	30.57±4.83	25.71±2.67	0.001	Significant
AGE (YEARS)	51.75±4.91	50.120±5.99	0.171	Not Significant

**Table 1:** Showed the mean body mass index (BMI) of type 2 male diabetic subjects (30.57±4.83 KG/M<sup>2</sup>) was observed to be significantly higher compared with that of the control subjects(30.57±4.83 VS 25.71±2.67; P=0.001 ). Whereas, the mean value of age did not show any significant difference in type 2 diabetic male subjects compared to control group (P=0.171)

\*Statistically significant at p≤0.05 \* BMI= Body mass index \* SD= Standard deviation

\* n= number of subjects in group \*

**TABLE 2:** Levels of glycated haemoglobin (HbA1c), luteinizing hormone, follicle stimulating hormone and testosterone in male diabetic and male control subjects (mean ±SD).

Parameter	DIABETIC	CONTROL	t-value	p value
	n=67	n=67		
HbA1c (%)	8.56±1.22	5.25±0.31	21.452	0.001*

LH (mIU/ml)	10.74±4.50	4.88±1.36	10.214	0.001*
FSH (mIU/ml)	15.13±7.26	6.89±2.92	8.620	0.001*
<b>TESTOSTERONE</b>				
(ng/ml)	2.89±1.05	5.08±1.30	-10.702	0.001*

**Table 2** : Showed the mean serum level of HbA1c, LH and FSH was observed to be significantly higher in type 2 diabetic male subjects when compared with control group (8.56±1.22 Vs 5.25±0.31; P =0.001) , (10.74±4.50 Vs 4.88±1.36; P =0.001) and (15.13±7.26 Vs 6.89 ± 2.92 ;P= 0.001) respectively. However, the mean serum levels of testosterone was observed to be significantly lower in type 2 diabetic male subjects in comparison to the control group (2.89±1.05 Vs 2.89±1.05; P=0.001) .

\* - Mean difference significant at  $p \leq 0.05$

**Key:**

n – Number of subjects in the group

SD – Standard Deviation

HbA1c – Glycated Haemoglobin

LH – Luteinizing Hormone

FSH – Follicle Stimulating Hormone

**TABLE 3:** Correlation of mean serum levels of glycated haemoglobin with mean serum levels of luteinizing hormone, follicle stimulating hormone and testosterone in type 2 diabetic male and control subjects

Parameter	DIABETIC		CONTROL	
	(n=67)		(n=67)	
	r	P value	R	P value
HbA1c & LH	0.385	0.001**	0.000	0.997
HbA1c & FSH	0.535	0.001**	0.461	0.001**
HbA1c & TESTOSTERONE	-0.043	0.731	0.168	0.173

**Table 3 :** Showed there was a significant positive correlation between the mean levels of HbA1c with mean serum levels of LH ( $r= 0.385$ ,  $p=0.001$ ) and FSH ( $r= 0.535$  ;  $p=0.001$ ) in type 2 diabetic male subjects . However, there was no significant correlation was noted in mean serum levels of HbA1c with mean serum levels of testosterone in the type 2 diabetic male subjects and control group ( $p>0.05$ ).

\*Correlation significant at  $p<0.05$ , \*\*Correlation significant at  $p<0.01$

**Key:**

r - Pearson Correlation Co-efficient

n – Number of subjects in the group

HbA1c – Glycated Haemoglobin

LH – Luteinizing Hormone

FSH – Follicle Stimulating Hormone

## DISCUSSION

The mean serum values of BMI and age in type 2 diabetic male subjects were observed to be significantly higher compared with that of the control subjects. This is in line with a study carried out by Gary *et al.*, in determination of the effects of elevated body mass index (BMI) on type 2 diabetes mellitus (DM) onset and its complications among elderly<sup>34</sup>. There were Elevated BMI values observed to be associated with progressively higher risk for all diabetes mellitus complications<sup>34</sup>. BMI is used to compare percentages of body fat, and elevated BMI values are associated with obesity<sup>43</sup>. A BMI of 27.3 kg/m<sup>2</sup> for women and greater than 27.8 kg/m<sup>2</sup> for males is considered obesity. <sup>42</sup>. A BMI greater than 27.5 kg/m<sup>2</sup> is classified as obesity and identified as a risk factor for diabetes mellitus, according to WHO categorization that was adopted by NIH panel experts<sup>43</sup>. Previous research, as reported by Logue *et al.* indicated that men with diabetes mellitus had increased BMIs, this is consistent with these findings. <sup>42</sup>. The results of this study showed that the type 2 diabetic male subjects' mean HbA1c levels were considerably higher than those of the control subjects. This aligns with cohort studies examining HBA1C variability in type 2 diabetic participants, which revealed higher HBA1C levels in male participants with diabetes<sup>44</sup>. Glycated hemoglobin or hemoglobin A1c is stated by the international federation of clinical chemistry working group (IFCC) 1 as Standard of Care(SOC) which is used for assessing and monitoring of history of blood glucose level<sup>38</sup>. It is used as an index of glycemic control. Glycated hemoglobin is an irreversible non enzymatic addition of a sugar residue to the hemoglobin, the rate of production is directly proportional to the glucose concentration. Monitoring of HbA1c is suggested by the American Diabetic association, American diabetic federation, and European association for the management of diabetes<sup>39</sup>. So HbA1c is now routinely obtained as the most prominent, single and independent parameter of

metabolic control. It is a risk factor for the growth and development of diabetic complications and significantly used in treatment and management<sup>39</sup>. Analysis of HbA1c in blood gives evidence about individual's average blood glucose levels in the period of 120days<sup>39</sup>.

The serum levels of LH and FSH were significantly higher in the test subjects as compared to the control group. Conversely, serum level of testosterone was observed to be significantly lower in type 2 diabetic subjects when compared with that of the control subject. This could be due to the effects of insulin resistance on the hypothalamus, pituitary glands and gonads, this causes less secretion of the gonadal steroids<sup>45</sup>. Furthermore, the aromatase enzyme, which converts testosterone to estradiol, may be the cause of the noticeably reduced testosterone levels. The ratio of testosterone to oestrogen is also an indicator of type 2 diabetes mellitus<sup>46</sup>. Additionally, it has been observed that insulin resistance lowers the quantity of leydig cells, which in turn alters the hormone testosterone concentration<sup>47</sup>. In diabetic patients, oxidative stress can also impair pituitary and hypothalamic function<sup>48</sup>, giving rise to a condition called hypogonadism<sup>49</sup>. The findings of this study are consistent with those of investigations conducted by Ezekiel et al. to ascertain the pattern and prevalence of hypogonadism in males with type 2 diabetes mellitus who are Nigerian<sup>35</sup>. It was discovered that the mean testosterone of type 2 diabetic men was significantly lower compared to the controls, the mean LH and FSH levels were significantly higher in type 2 diabetic men than the controls. Prior research were consistent these reports<sup>36 37</sup>.

The mean serum levels of HbA1c was significantly correlated positively with LH and FSH. However, the mean serum levels of HbA1c was not significantly correlated with testosterone in the test subjects and control subjects. This is in agreement with findings by Shewani et al which stated that as glycated haemoglobin (HbA1c) increases, LH and FSH increases and vice versa in type 2 diabetic male subjects<sup>27</sup>. Several studies have indicated association of HbA1C with LH and

FSH<sup>13,14,26</sup>. This is attributed to the interaction of gonadotrophin hormones and gonadal steroid hormone and their feed back mechanism at the hypothalamic pituitary axis in order to maintain homeostasis and spermatogenesis, produce healthy sperms with great density and regular testicular function especially diabetic conditions which is characterized by hyperglycemia<sup>11,12</sup>.

Hyperglycaemia causes tissue damage through multiple mechanisms including increased flux of glucose and other sugars through the polyol pathway, increased intracellular formation of advanced glycation end products (AGEs), increased expression of the receptor for AGEs and its activating ligands, activation of protein kinase C isoforms, and overactivity of the hexosamine pathway<sup>11</sup>. These pathways eventually lead to oxidative damage to testis, sperm. Testicular testosterone production is acutely reduced as a result of testicular dysfunction<sup>11</sup>. A decrease in testosterone levels increases the secretion of LH and FSH via negative feedback to hypothalamus and pituitary gland<sup>11</sup>. Further studies with adequate sample size are needed to validate the findings of this study. Also, Fertility hormonal assay should be included in the panel of tests conducted for diabetic individuals males.

## **Conclusion**

There were elevated levels of leutinizing hormone (LH), Follicle stimulating hormone (FSH) and significantly low levels of testosterone, as well as high levels of HBA1c (hyperglycemia) were revealed in this study. This is an indication of alteration in the hypothalamic-pituitary -gonadal axis which could lead to male infertility.

**Ethical approval:** All authors hereby declare that the experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki

## REFERENCES

1. Carolina Solis-Herrera M D, Curtis Triplitt Pharm D, Charles Reasner M D, Ralph A, DeFronzo, M D, Eugenio Cersosimo M D. Classification and Diagnosis of Diabetes Mellitus: Standards of Medical Care in Diabetes. *Diabet Care*.2018. 41 (1): 13-27.
2. Magliano D J, Boyko E J. IDF Diabetes Atlas 10th edition scientific committee .Brussels:International Diabetes Federation; 2021.5:6-7.
3. Oladapo O, Salako L, Sodiq O, Shoyinka K, Adedapo K ,Falase A. A prevalence of cardiometabolic risk factors among a rural Yoruba south-western Nigeria population: a population based survey. *J Cardio Afri*; 2010. 21: 26-31.
4. Sabir A, Isezuo, S, Ohwovoriole A.. Dysglycaemia and its risk factors in an urban Fulani population of northern Nigeria. *West Afri J Med*.2011; 30:325-330.
5. Uloko A, Musa B, Ramalan M, Gezawa I, Puepet F, Uloko A, Borodo M, Sada K. Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta- analysis. *Diabetes Ther*, 9(3), 1307-1316.
6. Arthur C, Hall J. Guyton and Hall textbook of medical physiology. 2nd Edition. Elsevier.2017.113-
7. Vanbroght M ,Wyns C . Fertility and infertility: Definition and epidemiology.*Clinical biochemistry. j.clinbiochem*. 2018; 62 : 2 -10. doi: 10.1016/j.clinbiochem..
8. Ding GL, Liu Y, Liu M E,. The effects of diabetes on male fertility and epigenetic regulation during spermatogenesis. *Asian J Androl*. 2015;17(6):948–953.
9. Huang R, Chen J, Guo B, Jiang C, Sun W. Diabetes-induced male infertility: potential mechanisms and treatment options. *Mol med*.2024; 30:11-15.
10. Berta L S . Hormones and receptors in sexual reproduction.*Int Med Bio Sci*.2022;78(7)20-22.
11. Darbandi M, Darbandi S, Agarwal A. Reactive oxygen species and male reproductive hormones. *Reprod Biol Endocrinol* .2018.16:87-90. <https://doi.org/10.1186/s12958-018-0406-2>.
12. Barazani Y, Katz B, Nagler H, Stember D. Lifestyle, environment, and male reproductive health. *Urol Cli Nor Am*, 41(1):55–66.
13. George J T, Veldhuis J D, Tena-Sempere M ,Millar R P, Anderson R A. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. *Clin Endocrinol (Oxf)* 2013;79:100–104.
14. Ghazi S, Zohdy W, Elkhiat Y, Shamloul R. Serum testosterone levels in diabetic men with and without erectile dysfunction. *Andrologia*. 2012;44:373–80
15. Al Hayek AA, Khader YS, Jafal S, Khawaja N, Robert AA, Ajlouni K. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. *J Family Community Med*. 2013 20(3):179-186. doi: 10.4103/2230-8229.122006.

16. Serwaa D, Bello F A, Osungbade K O, Nkansah C, Osei-Boakye F, Appiah SK. Prevalence and determinants of low testosterone levels in men with type 2 diabetes mellitus; a case-control study in a district hospital in Ghana. *PLOS Glob Public Health*.2021. 1(12): 23-25. <https://doi.org/10.1371/journal.pgph.0000052>
17. Wu F C W, Tajar A, Beynon J M, Pye S R, Silman A J, Finn J D. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med*. 2010;363(2):123–35.
18. Swerdloff R, Wang C. Testosterone treatment of older men—why are controversies created? Oxford University Press; 2011.
19. Basaria S. Male hypogonadism. *Lancet*. 2014;383(9924):1250–1263. pmid:24119423
20. Cheung KK, Luk AO, So WY, Ma RC, Kong AP, Chow FC, Chan JC. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. *J Diabetes Investig*. 2015 ;(2):112-23. doi: 10.1111/jdi.12288.
21. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insights*. 2016 ;11:95-104. doi: 10.4137/BMI.S38440.
22. Alhassan Z, Watson, M, Budgen D, Alshammari , R, Alessa A, Moubayed A. Improving Current Glycated Hemoglobin Prediction in Adults: Use of Machine Learning Algorithms With Electronic Health Records. *JMIR Medical Inform*.9(5), e25237-e25238.
23. Gavriilidou NN, Pihlsgård M, Elmståhl S. Anthropometric reference data for elderly Swedes and its disease-related pattern. *Eur J Clin Nutr*. 2015 ;69(9):1066-1075.
24. Kidy FF, Dhalwani N, Harrington DM, Gray LJ, Bodicoat DH, Webb D, Davies MJ, Khunti K. Associations Between Anthropometric Measurements and Cardiometabolic Risk Factors in White European and South Asian Adults in the United Kingdom. *Mayo Clin Proc*. 2017 ;92(6):925-933.
25. Al-Fartosy A, Mohammed, I. Study the Biochemical Correlation of Insulin Resistance with HbA1c and Sex Hormones in NIDDM Patients/Meisan-Iraq. *J Diabet Melli*.2017; 7: 302-315. doi: [10.4236/jdm.2017.74025](https://doi.org/10.4236/jdm.2017.74025).
26. Khowailed A, Mohammad O, Elattar S, Gaber S. Effect of Sildenafil on Gonadotrophin and Sex Steroids in Fructose Induced Diabetes in Female Rats. *The Medical Journal of Cairo University*.2012;80:243-252.
27. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insights*. 2016;11:95-104. doi: 10.4137/BMI.S38440.
28. Oduwole OO, Huhtaniemi IT, Misrahi M. The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited. *Int J Mol Sci*. 2021;22(23):127-135. doi: 10.3390/ijms222312735.
29. Parmar Ramkesh S, Verma S, Neelkamal K, Pathak Vineet K, Bhadoria AS. Prevalence of erectile dysfunction in Type 2 diabetes mellitus (T2DM) and its predictors among diabetic men. *J Fam Med Pri Care*.2022;11(7):3875-3875 DOI: 10.4103/jfmprc.jfmprc\_1130\_21
30. Metus P, Ruzzante N, Bonvicini P, Meneghetti M, Zaninotto M, Plebani M. Immunoturbidimetric assay of glycated hemoglobin. *J Clin Lab Anal*1999.13 :(1) 5-8.
31. Bernard DJ, Ongaro L. The Ultrasensitive Luteinizing Hormone (LH) ELISA Gets a New Lease on Life. *Endocrinology*.2022; 163(10):123-125. doi: 10.1210/endocr/bqac123.

32. Ongaro L, Alonso CAI, Zhou X, Brûlé E, Li Y, Schang G, Parlow AF, Steyn F, Bernard DJ. Development of a Highly Sensitive ELISA for Measurement of FSH in Serum, Plasma, and Whole Blood in Mice. *Endocrinology*. 2021;162(4):14-18.doi: 10.1210/endo/bqab014.
33. Tietz N.. *Textbook of clinical chemistry*. 1986.Saunderspublishers.
34. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009 ;373(9669):1083-1096. doi: 10.1016/S0140-6736(09)60318-4.
35. Ezekiel M, Jibril M, Sani-Bello F, Bakar A. Hypergonadotropic hypogonadism in Nigerian men with type 2 diabetes mellitus. *Clin Diabetol*.2021;10, 1-2.
36. Ogbera O, Sonny C, Olufemi F. Hypogonadism and subnormal total testosterone levels in men with type 2 diabetes mellitus. *J Coll Physic and Surg Pakis* 2011;21(9), 517–521.
37. Paruk I, Pirie F, Nkwanyana N. (2019). Prevalence of low serum testosterone levels among men with type 2 diabetes mellitus attending two outpatient diabetes clinics in KwaZulu-Natal Province, South Africa. *J S Afri Med* .2019;109(12): 963–970.
38. International Diabetes Federation. *"Facts & figures"*. *Archived* from the original on 2023-08-10.
39. Ravindra M, Deepthi S. Comparison of HbA1c values by immunoturbidimetric and HPLC methods.*Med. Pul*.2019;12 :2-6.
40. Nassar GN, Leslie SW. Physiology, Testosterone. [Updated 2023 Jan 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 . Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526128/>
41. Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Wild SH, Sattar N.Scottish Diabetes Research Network Epidemiology Group. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia*. 2011;54(12):3003-3006. doi: 10.1007/s00125-011-2313-3
42. Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. [Updated 2023 May 4]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279167/>
43. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report*. National Institutes of Health. *Obes Res*. 1998;6 2:51–209.
44. Akselrod D, Friger M, Biderman, A. HbA1C variability among type 2 diabetic patients: a retrospective cohort study. *Diabetol Metab Syndr*.2021;101:717-725. <https://doi.org/10.1186/s13098-021-00717-5>
45. Schoeller EL, Schon S.The effects of type 1 diabetes on the hypothalamic, pituitary and testes axis. *Cell Tissue Res*. 2012;349:839-847.
46. Cheung KK, Luk AO. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. *J Diabetes Investig*. 2015;6:112-123.
47. Hofny ER, Ali ME. Semen parameters and hormonal profile in obese fertile and infertile males. *Fertil Steril*. 2010; 94:581-584.
48. Muriach M, Flores-Bellver M. Diabetes and the brain: Oxidative stress, inflammation, and autophagy. *Oxid Med Cell Longev*. 2014;12:102-158.

49. Russo V, Chen R, Arnemento-Villareal, R. Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review. *Front. Endocrinol.*2021.11:2-12. <https://doi.org/10.3389/fendo.2020.607240>.

UNDER PEER REVIEW